PROCEPT BioRobotics Corporation
Case Overview
57 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 09/22/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: PROCEPT BioRobotics Corporation |
| Court: | Court: Northern District of California |
| Case Number: | Case Number: 5:26cv07691 |
| Class Period: | Class Period: 02/28/2024 - 02/25/2026 |
| Ticker: | Ticker: PRCT |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The lawsuit alleges that Procept made materially false and misleading statements and/or failed to disclose: (i) that during the Class Period, Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated the Company’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of the foregoing, Defendants’ representations during the Class Period regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of the foregoing, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of the foregoing, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
On August 6, 2025, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately 12,750 handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship 13,350 units the following quarter, down from consensus estimates of over 13,840 units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept’s stock price fell from $45.69 per share on August 6, 2025 to close at $38.41 per share on August 8, 2025, a decline of approximately 16%.
On November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold 13,225 handpieces, missing the Company’s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from 53,000 to 52,000 units. Additionally, when pressed by analysts
regarding the lowered handpiece guidance, CEO Larry L. Wood admitted that Procept had not “been managing customer inventory by establishing par levels” and that some customers were “probably carrying too much.” On this news, Procept’s stock price fell from $35.02 per share on November 4, 2025 to close at $31.30 per share on November 6, 2026, a decline of over 10%.
On February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over 10,000 units. As a result, Procept handpiece unit sales in the U.S. declined from 13,225 units in the third quarter to 9,400 units in the fourth quarter, a nearly 30% decline. Additionally, Procept revealed that the Company was eliminating a longstanding (but previously undisclosed) discount program that had incentivized customers to place bulk orders “[during] the final weeks” of every quarter, impairing the Company’s ability to make additional handpiece sales in subsequent quarters. On this news, Procept’s stock price fell over two trading days, from $27.84 per share on February 25, 2026 to close at $22.69 per share on February 27, 2026, a decline of over 18%.
On August 6, 2025, Procept announced earnings results for its second fiscal quarter of 2025, revealing that handpiece unit shipments had unexpectedly deteriorated as the Company has sold approximately 12,750 handpieces in the U.S. during the quarter. That same day, Procept announced it expected to ship 13,350 units the following quarter, down from consensus estimates of over 13,840 units. Additionally, CEO Reza Zadno announced that Procept was eliminating the role of Chief Commercial Officer. On this news, Procept’s stock price fell from $45.69 per share on August 6, 2025 to close at $38.41 per share on August 8, 2025, a decline of approximately 16%.
On November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that the Company had sold 13,225 handpieces, missing the Company’s guidance set during the previous quarter. The Company also announced it was reducing its annual handpiece sales guidance by 1,000 units, from 53,000 to 52,000 units. Additionally, when pressed by analysts
regarding the lowered handpiece guidance, CEO Larry L. Wood admitted that Procept had not “been managing customer inventory by establishing par levels” and that some customers were “probably carrying too much.” On this news, Procept’s stock price fell from $35.02 per share on November 4, 2025 to close at $31.30 per share on November 6, 2026, a decline of over 10%.
On February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year, revealing that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential that had grown over time, resulting in cumulative excess field inventory of over 10,000 units. As a result, Procept handpiece unit sales in the U.S. declined from 13,225 units in the third quarter to 9,400 units in the fourth quarter, a nearly 30% decline. Additionally, Procept revealed that the Company was eliminating a longstanding (but previously undisclosed) discount program that had incentivized customers to place bulk orders “[during] the final weeks” of every quarter, impairing the Company’s ability to make additional handpiece sales in subsequent quarters. On this news, Procept’s stock price fell over two trading days, from $27.84 per share on February 25, 2026 to close at $22.69 per share on February 27, 2026, a decline of over 18%.